AIRDOC-B (02251) has issued a profit warning, projecting a net loss of no more than RMB 50 million for the first half of 2026, a sharp reversal from the net profit of approximately RMB 440,000 recorded in the same period of 2025.

The anticipated swing into the red is attributed to several key factors. Firstly, the company has significantly increased its investment in research and development, as well as clinical trials. This includes heightened spending on the "Wanyu" medical large language model, AI Agent development across its product lines, computing power, and medical data governance, alongside the advancement of multi-center clinical studies, device registrations, and compliance-driven commercialization efforts.

Secondly, the PBM-AI myopia prevention and control business remains in an early expansion and cultivation phase. While the number of partner stores, users, and model calls has grown, this has led to higher expenditures in marketing, medical services, store deployment, operations, and consumer-side eye health campaigns. Revenue contributions and economies of scale from this segment have yet to materialize.

Additionally, foreign exchange fluctuations have also exerted some impact on the group's financial position. In response, the company has reorganized its organizational structure, leveraging the "Wanyu" large model to empower its mid and back-office functions. This strategic move aims to reduce costs and enhance operational efficiency, thereby partially offsetting the aforementioned financial pressures.